Cautionary Statement Relating to Forward Looking Statements

See Note 3 - Discontinued Operations

See Note 6 - Business Combinations.

Three Months Ended June 30, 2022, Compared With Three Months Ended June 30, 2021

Six Months Ended June 30, 2022, Compared With Six Months Ended June 30, 2021

*Please note this reconciliation does not include HOLO Portal capitalized costs of $0.4 million and $0.0 million for the three months ended June 30, 2022 and 2021, and $0.4 million and $0.0 million for the six months ended June 30, 2022 and 2021.

Diluted Share Common Shares Diluted Share Net loss from continuing operations

$ (0.86) $ (10,639) $ (2.79) Change in fair value of warrant liability

Non-GAAP net loss from continuing operations $ (12,654) $ (1.91) $ (9,230) $ (2.41)

*Please note this reconciliation does not include HOLO Portal capitalized costs of $0.4 million and $0.0 million for the three months ended June 30, 2022 and 2021.

Diluted Share Common Shares Diluted Share Net loss from continuing operations

$ (0.92) $ (25,829) $ (7.29) Change in fair value of warrant liability

Non-GAAP net loss from continuing operations $ (26,881) $ (4.37) $ (19,748) $ (5.57)

*Please note this reconciliation does not include HOLO Portal capitalized costs of $0.4 million and $0.0 million for the six months ended June 30, 2022 and 2021.

Reconciliation of Net Loss Applicable to Common Shares to Adjusted EBITDA

(8,488) $ (25,048) $ (18,267) Adjusted EBITDA as a percent of revenues

*Please note this reconciliation does not include HOLO Portal capitalized costs of $0.4 million and $0.0 million for the three months ended June 30, 2022 and 2021, and $0.4 million and $0.0 million for the six months ended June 30, 2022 and 2021.

2022 and 2021 Foreign exchange (gain) loss - These costs relate to the process of remeasuring international activity into the Company's functional currency.

2022 Change in fair value of warrant liability - Other income related to the revaluation of our warrant liability.

2022 and 2021 Gain on acquisition contingency - The gain on acquisition contingency relates to an adjustment to our estimate of obligation for future milestone payments on the Holo Surgical acquisition.

2022 and 2021 Asset impairment and abandonments - These costs relate to asset impairment and abandonments of certain long-term assets within the asset group.

2022 and 2021 Transaction and integration expenses - These costs relate to professional fees associated with financings and with the acquisition of Holo Surgical and Prompt Prototypes, and other matters.

2022 Inventory write-off - These costs relate to inventory write-offs for product rationalization.

2021 Bargain purchase gain - Gain related to our acquisition of Prompt Prototypes, LLC.

2021 Severance and restructuring costs - These gain and costs relate to the reduction of our organizational structure, primarily driven by simplification of our Marquette, MI location.

Non-GAAP Three Months Ended June 30, 2022, Compared With Non-GAAP Three Months Ended June 30, 2021

Non-GAAP Six Months Ended June 30, 2022, Compared With Non-GAAP Six Months Ended June 30, 2021

As the global outbreak of COVID-19 continues to rapidly evolve, it could continue to materially and adversely affect our revenues, financial condition, profitability, and cash flows for an indeterminate period of time.

On June 14, 2021, we issued and sold in a registered direct offering an aggregate of 966,183 shares of our common stock and investor warrants to purchase up to an aggregate of 966,183 shares at a strike price of $51.7500. The

The following table presents a summary of our cash flow activity for the periods set forth below (in thousands):

For the Six Months Ended

At June 30, 2022, we had 90 days of revenues outstanding in trade accounts receivable, an increase of 13 days compared to December 31, 2021. The increase is primarily due to timing of collections from our customers.

At June 30, 2022, excluding the purchase accounting step-up of Paradigm inventory, we had 514 days of inventory on hand, an increase of 90 days compared to December 31, 2021. The increase in inventory days is primarily due

to the continued purchase of implants during six months ended June 30, 2022. We believe that our inventory levels will be adequate to support our on-going operations.

As of June 30, 2022, we have no material off-balance sheet arrangements.

The following table provides a summary of our operating lease obligations and other significant obligations as of June 30, 2022:

Contractual Obligations Due by Period

(1)These amounts consist of contractual obligations for capital expenditures, open purchase orders and minimum purchase obligations.

© Edgar Online, source Glimpses